To appraise the clinical and cost-effectiveness of Encorafenib in combination with cetuximab and/or binimetinib within its marketing authorisation for colorectal cancer
Status In progress
Process TAG
ID number 1598

Provisional Schedule

Expected publication 22 July 2020


Key events during the development of the guidance:

Date Update
02 May 2019 In progress, Referred 8 January 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance